WebMD – Jan. 18
Backer found his high-tech hope for survival at Tampa's Moffitt Cancer Center. He turned to a Moffitt clinical trial in cancer immunotherapy called CAR T cell therapy
WFTV – Jan. 18
But Florida Hospital’s proposal promises to bring a $100 million investment to the facility, and a partnership with Moffit Cancer Center to launch its research facility.
Orlando Sentinel – Jan. 18
Florida Hospital is planning to partner with the Moffitt Cancer Center in Tampa, and establish five core programs at the facility, including translational research, drug discovery, a precision medicine research clinic, Phase 1 clinical research and a stem cell laboratory.
Tampa Bay Times – Jan. 17
Yet when he learned that he had Hodgkin’s Lymphoma, a highly treatable form of cancer, his spirit rebounded. And when he began chemotherapy treatments at Moffitt Cancer Center, his strength returned.
Bay News 9 – Jan. 14
The bicyclists are participating in the "Cure on Wheels" ride that kicks off "Moffitt Day" in the state capitol. And it will take the riders four days to get there.
PR Web – Jan. 17
Dr. Jain has participated in a number of selected research/publications for prestigious cancer such as: Moffitt Cancer Center and MD Anderson Cancer Center and journals such as: American Journal of Clinical Oncology and Journal of Thoracic Diseases. He has participated in presentations such as ASCO and Diseases Society of America (IDSA) 44th Annual Meeting, Ontario.
Herald Tribune – Jan. 16
With the closest National Cancer Institute-designated hospital — Moffitt Cancer Center — more than an hour’s drive away in Tampa, the quest to develop a premier treatment program here reflects not only this region’s growth, but also an evolution in the practice and science of oncology.
Reader’s Digest – Jan. 16
“The goal of T-cell receptor therapy is to create T cells, using a process like CAR T, that can recognize those changes and attack cancers but leave healthy cells alone,” explains Frederick L. Locke, MD, vice chair of the department of cellular immunotherapy at Moffitt Cancer Center in Tampa, Florida, and a principal investigator for the Yescarta clinical trials.
Patch – Jan. 15
George & Doretha Edgecomb: This power couple was influential in a variety of fields. George Edgecomb, who died of leukemia at age 33 in 1976, was Hillsborough County's first black prosecutor and judge, and a community leader. His name adorns the George Edgecomb Courthouse, the George Edgecomb Bar Association and the George Edgecomb Society at H. Lee Moffitt Cancer Center. Doretha, Edgecomb, a lifelong educator, has served as a teacher, reading supervisor, drug prevention coordinator, principal and three-term member of the Hillsborough County School Board.
MedPage Today – Jan. 15
CancerCare CEO Patricia J. Goldsmith told MedPage Today that she thought that "third time was the charm" concerning the cancer.com site. She had a professionally long history with the URL, she explained, going back to when she was a senior administrator at the Moffitt Cancer Center in Tampa, Florida, in the 1990s, and learned that Ortho Biotech owned cancer.com.
Orlando Medical News – Jan. 14
Leena Kamat, MD, is a board certified diagnostic radiologist, sub-specialized in breast imaging for Radiology Specialists of Florida at Florida Hospital. She earned her medical degree at the University of Florida, College of Medicine and following graduation completed her residency at the University of South Florida and a fellowship in breast imaging at the Moffitt Cancer Center.
Cure – Jan. 14
A team of scientists from 10 different cancer centers around the globe – including Moffitt Cancer Center and UCLA – assessed 60 adults with advanced desmoplastic melanoma who received either Keytruda (pembrolizumab) or Opdivo (nivolumab).
Infosurhoy – Jan. 12
However, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.